|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
EP0854720B1
(en)
*
|
1995-10-10 |
1999-08-04 |
Pfizer Inc. |
Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
|
|
US20030219863A1
(en)
*
|
1997-01-31 |
2003-11-27 |
Bristol-Myers Squibb Company |
Soluble CTLA4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
RU2287340C2
(ru)
*
|
2000-07-03 |
2006-11-20 |
Бристол-Маерс Сквибб Компани |
Способы лечения ревматических заболеваний с применением растворимого ctla4
|
|
PL375139A1
(en)
*
|
2001-01-26 |
2005-11-28 |
Emory University |
Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
|
|
HU229680B1
(hu)
*
|
2001-05-23 |
2014-04-28 |
Bristol Myers Squibb Co |
Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
|
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
|
AU2003234469A1
(en)
*
|
2002-05-02 |
2003-11-17 |
University Of Connecticut Health Center |
Use of heat shock proteins to enhance efficacy of antibody therapeutics
|
|
ATE458500T1
(de)
*
|
2003-11-14 |
2010-03-15 |
Genvec Inc |
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
|
|
US7588772B2
(en)
*
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
WO2008153541A1
(en)
|
2006-09-26 |
2008-12-18 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
AU2008319053B2
(en)
|
2007-11-01 |
2012-04-26 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
EP3124491B1
(en)
|
2009-06-05 |
2019-10-30 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
CN103153332A
(zh)
|
2010-09-28 |
2013-06-12 |
卡尔医疗有限公司 |
用于治疗血液恶性肿瘤的组合物和方法
|
|
AU2012243039B2
(en)
|
2011-04-08 |
2017-07-13 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
EP3563834A1
(en)
|
2012-02-07 |
2019-11-06 |
Infectious Disease Research Institute |
Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
|
|
EA034351B1
(ru)
|
2012-05-16 |
2020-01-30 |
Иммьюн Дизайн Корп. |
Трехкомпонентная вакцина против впг-2 и способы ее применения
|
|
CN105209047B
(zh)
|
2013-04-18 |
2020-08-18 |
免疫设计股份有限公司 |
用于癌症治疗的gla单一疗法
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
CA3023968A1
(en)
|
2016-05-16 |
2017-11-23 |
Infectious Disease Research Institute |
Formulation containing tlr agonist and methods of use
|
|
AU2017273650B2
(en)
|
2016-06-01 |
2022-08-18 |
Access To Advanced Health Institute |
Nanoalum particles containing a sizing agent
|
|
KR102755593B1
(ko)
|
2017-09-08 |
2025-01-20 |
액세스 투 어드밴스드 헬스 인스티튜트 |
사포닌을 포함하는 리포솜 제형 및 사용 방법
|